Resveratrol decreases periodontal breakdown and modulates local levels of cytokines during periodontitis in rats

Journal of Periodontology

Volumn 84, Issue 10, 2013, Pages

  Casati, Marcio Z ^a   Algayer, Carolina ^a   Da Cruz, Geisa Cardoso ^a   Ribeiro, Fernanda V ^a   Casarin, Renato C V ^a   Pimentel, Suzana P ^a   Cirano, Fabiano R ^a  

^a PAULISTA UNIVERSITY   (Brazil)

Author keywords

Alveolar bone loss; Anti bacterial agents; Anti inflammatory agents; Medicinal; Periodontitis; Plants; Resveratrol

Indexed keywords

CYTOKINE; IL17 PROTEIN, RAT; IMMUNOLOGIC FACTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; PLACEBO; RESVERATROL; STILBENE DERIVATIVE;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BIOFILM; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; GINGIVA; IMMUNOLOGY; MALE; PERIODONTITIS; RANDOMIZATION; RAT; WISTAR RAT;

ALVEOLAR BONE LOSS; ANIMALS; BIOFILMS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GINGIVA; IMMUNOLOGIC FACTORS; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-4; MALE; PERIODONTITIS; PLACEBOS; RANDOM ALLOCATION; RATS; RATS, WISTAR; STILBENES;

EID: 84884852318     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2013.120746     Document Type: Article

References (41)

1. Burt B; Research, Science and Therapy Committee of the American Academy of Periodontology. Position paper: Epidemiology of periodontal diseases. J Periodontol 2005;76:1406-1419.
2. Kinane DF, Preshaw PM, Loos BG; Working Group 2 of Seventh European Workshop on Periodontology. Host-response: Understanding the cellular and molecular mechanisms of host-microbial interactions-Consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 2011;38 (Suppl 11):44-48.
3. Bloemen V, Schoenmaker T, de Vries TJ, Everts V. IL-1b favors osteoclastogenesis via supporting human periodontal ligament fibroblasts. J Cell Biochem 2011; 112:1890-1897.
4. Garlet GP. Destructive and protective roles of cytokines in periodontitis: A re-appraisal from host defense and tissue destruction viewpoints. J Dent Res 2010; 89:1349-1363.
5. Cardoso CR, Garlet GP, Crippa GE, et al. Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol Immunol 2009;24:1-6.
6. Dutzan N, Gamonal J, Silva A, Sanz M, Vernal R. Overexpression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL)-17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis. J Clin Periodontol 2009;36:396-403.
7. Santos VR, Ribeiro FV, Lima JA, Napimoga MH, Bastos MF, Duarte PM. Cytokine levels in sites of chronic periodontitis of poorly controlled and wellcontrolled type 2 diabetic subjects. J Clin Periodontol 2010;37:1049-1058.
8. Gurgel BC, Duarte PM, Nociti FH Jr., et al. Impact of an anti-inflammatory therapy and its withdrawal on the progression of experimental periodontitis in rats. J Periodontol 2004;75:1613-1618.
9. Holzhausen M, Spolidorio DM, Muscará MN, Hebling J, Spolidorio LC. Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats. J Periodontal Res 2005;40: 208-211. (Pubitemid 40655847)
10. Sekino S, Ramberg P, Lindhe J. The effect of systemic administration of ibuprofen in the experimental gingivitis model. J Clin Periodontol 2005;32:182-187. (Pubitemid 40341853)
11. Aras H, Caǧlayan F, Güncü GN, Berberoǧlu A, Kilincx K. Effect of systemically administered naproxen sodium on clinical parameters and myeloperoxidase and elastase-like activity levels in gingival crevicular fluid. J Periodontol 2007;78:868-873.
12. Azoubel MC, Sarmento VA, Cangussú V, et al. Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: Short-term evaluation. J Periodontol 2008;79:1719-1725.
13. Queiroz-Junior CM, Pacheco CM, Maltos KL, Caliari MV, Duarte ID, Francischi JN. Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats. J Periodontal Res 2009;44: 153-160.
14. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-442. (Pubitemid 32747607)
15. Toker H, Ozan F, Ozer H, Ozdemir H, Eren K, Yeler H. A morphometric and histopathologic evaluation of the effects of propolis on alveolar bone loss in experimental periodontitis in rats. J Periodontol 2008;79: 1089-1094.
16. Napimoga MH, Benatti BB, Lima FO, et al. Cannabidiol decreases bone resorption by inhibiting RANK/ RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol 2009;9:216-222.
17. Barrella GE, Suffredini IB, Ribeiro FV, Cirano FR, Pimentel SP. Evaluation of the effect of an organic extract obtained from Ipomoea alba L. on experimental periodontitis in rats. Braz Oral Res 2012;26: 158-164.
18. Ribeiro FV, Barrella GE, Casarin RC, Cirano FR, Foglio MA, Pimentel SP. Effect of crude extract and essential oil of Cordia verbenacea in experimental periodontitis in rats. Braz J Oral Sci 2012;11:42-46.
19. Singh SU, Casper RF, Fritz PC, et al. Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol 2000;167:183-195.
20. Soufi FG, Sheervalilou R, Vardiani M, Khalili M, Alipour MR. Chronic resveratrol administration has beneficial effects in experimental model of type 2 diabetic rats. Endocr Regul 2012;46:83-90.
21. Xuzhu G, Komai-Koma M, Leung BP, et al. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis 2012;71:129-135.
22. Whitlock NC, Baek SJ. The anticancer effects of resveratrol: Modulation of transcription factors. Nutr Cancer 2012;64:493-502.
23. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol 2011;667:258-264.
24. Li Z, Pang L, Fang F, et al. Resveratrol attenuates brain damage in a rat model of focal cerebral ischemia via up-regulation of hippocampal Bcl-2. Brain Res 2012;1450:116-124.
25. Breen DM, Dolinsky VW, Zhang H, et al. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis 2012;222:375-381.
26. Tseng PC, Hou SM, Chen RJ, et al. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 2011;26: 2552-2563.
27. Tonetti MS, Chapple IL; Working Group 3 of Seventh European Workshop on Periodontology. Biological approaches to the development of novel periodontal therapies-Consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 2011;38(Suppl. 11):114-118.
28. Martín AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004;67:1399-1410. (Pubitemid 38315105)
29. Sharma S, Kulkarni SK, Chopra K. Effect of resveratrol, a polyphenolic phytoalexin, on thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Fundam Clin Pharmacol 2007;21:89-94. (Pubitemid 46096187)
30. van Ginkel PR, Sareen D, Subramanian L, et al. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 2007;13: 5162-5169. (Pubitemid 47502085)
31. Schmatz R, Mazzanti CM, Spanevello R, et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol 2009;610: 42-48.
32. Fernandes MI, Gaio EJ, Oppermann RV, Rados PV, Rosing CK. Comparison of histometric and morphometric analyses of bone height in ligature-induced periodontitis in rats. Braz Oral Res 2007;21:216-221.
33. Gemmell E, Seymour GJ. Immunoregulatory control of Th1/Th2 cytokine profiles in periodontal disease. Periodontol 2000 2004;35:21-41. (Pubitemid 41742817)
34. Santos VR, Ribeiro FV, Lima JA, et al. Partial-and fullmouth scaling and root planing in type 2 diabetic subjects: A 12-mo follow-up of clinical parameters and levels of cytokines and osteoclastogenesisrelated factors. J Periodontal Res 2012;47:45-54.
35. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008;223:87-113. (Pubitemid 351986173)
36. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203:2673-2682. (Pubitemid 44833343)
37. Duarte PM, Miranda TS, Lima JA, et al. Expression of immune-inflammatory markers in sites of chronic periodontitis in patients with type 2 diabetes. J Periodontol 2012;83:426-434.
38. Chen LL, Wang SX, Dai Y, et al. Effect of catch-up growth by various dietary patterns and resveratrol intervention on bone status. Exp Biol Med (Maywood) 2012;237:297-304.
39. Rizzo A, Bevilacqua N, Guida L, Annunziata M, Romano Carratelli C, Paolillo R. Effect of resveratrol and modulation of cytokine production on human periodontal ligament cells. Cytokine 2012;60:197-204.
40. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999;6:79-84. (Pubitemid 129634463)
41. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. Immunomodulatory activity of resveratrol: Suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 2001;62:1299-1308. (Pubitemid 33055634)